2
عمومی::
نارسایی قلبی
Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure
Health-related quality of life (HRQL) is known to be markedly reduced in patients with heart failure, even compared with HRQL typical of patients with other chronic diseases.
The Prospective Comparison of ARNI With an ACE-Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial, which found that sacubitril/valsartan, compared with enalapril, significantly reduced cardiovascular mortality, heart failure-associated hospitalization, and all-cause mortality in patients with heart failure and reduced ejection fraction, also found improvement in overall HRQL in surviving patients, as determined by the Kansas City Cardiomyopathy Questionnaire (KCCQ).
The KCCQ domains have limited granularity for describing limitations in individual activities that are particularly important to patients with heart failure.
The PARADIGM-HF trial was a randomized, double-blind, active treatment-controlled, clinical trial performed from performed from December 8, 2009, to March 31, 2014, that enrolled patients 18 years or older who had heart failure and left ventricular ejection fraction (LVEF) of 40% or less, New York Heart Association (NYHA) class II to IV disease, and a serum brain-type natriuretic peptide (BNP) level greater than 150 pg/mL, an N-terminal pro-brain-type natriuretic peptide (NT-proBNP) level greater than 600 pg/mL (to convert BNP and NT-proBNP levels to nanograms per liter, multiply by 1), or a heart failure-associated hospitalization within 12 months before enrollment.
واژگان شبکه مترجمین ایران